The Enterprise Value as of November 2024 (TTM) for Merus N.V. (MRUS) is 2.68B

According to Merus N.V.’s latest financial reports and current stock price. The company's current Enterprise Value is 2.68B. This represents a change of 12.09% compared to the average of 2.39B of the last 4 quarters.

Merus N.V. (MRUS) Historical Enterprise Value (quarterly & annually)

How has MRUS Enterprise Value performed in the past?

The mean historical Enterprise Value of Merus N.V. over the last ten years is 391.01M. The current 2.68B Enterprise Value has changed 68.52% with respect to the historical average. Over the past ten years (40 quarters), MRUS's Enterprise Value was at its highest in in the September 2024 quarter at 2.98B. The Enterprise Value was at its lowest in in the December 2017 quarter at -179569066.00.

Merus N.V. (MRUS) Enterprise Value by Quarter and Year

Discovering the peaks and valleys of Merus N.V. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Merus N.V. (MRUS) Average Enterprise Value

How has MRUS Enterprise Value performed in the past?

The current Enterprise Value of Merus N.V. (MRUS) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

Merus N.V. (MRUS) Enterprise Value vs. Peers

How is MRUS’s Enterprise Value compared to its peers?

Merus N.V.’s Enterprise Value is greater than Anebulo Pharmaceuticals, Inc. (36.46M), greater than Adagene Inc. (22.22M), greater than Acrivon Therapeutics, Inc. Common Stock (163.47M), greater than AnaptysBio, Inc. (502.56M), greater than Mineralys Therapeutics, Inc. (523.81M), less than Crinetics Pharmaceuticals, Inc. (4.93B), greater than Inhibrx Biosciences, Inc. (9.32M), greater than Lyell Immunopharma, Inc. (216.40M), greater than Kronos Bio, Inc. (5.32M), greater than Kura Oncology, Inc. (807.00M), greater than Protagonist Therapeutics, Inc. (2.65B), greater than Replimune Group, Inc. (984.10M), less than Cerevel Therapeutics Holdings, Inc. (8.24B), less than Vaxcyte, Inc. (10.01B), greater than Larimar Therapeutics, Inc. (363.34M), greater than Syndax Pharmaceuticals, Inc. (1.24B), greater than Sutro Biopharma, Inc. (57.26M),

Build a custom stock screener for Merus N.V. (MRUS) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Merus N.V. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Merus N.V. (MRUS) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Merus N.V. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.